Aardvark Therapeutics (AARD) reported a net loss of $19.2 million, or $0.88 per basic and diluted share, for the third quarter ended September 30, 2026. Research and development expense was $15.7 million, while general and administrative expense was $4.0 million.
The FDA lifted the clinical hold on ARD-101 for hyperphagia in Prader-Willi syndrome in October. Aardvark said it has an FDA meeting scheduled for the first quarter of 2027 and expects to resume PWS clinical activities in 2027, subject to FDA alignment.
- Cash, cash equivalents and short-term investments totaled $60.3 million as of September 30, 2026.
- The company said its existing cash resources are expected to fund projected operations through 2027.
- The FDA agreed Aardvark may conduct an open-label ARD-101 trial at 200 mg twice daily in patients with PWS.
- The terminated HERO trial randomized 67 of 90 planned participants; the company described efficacy data as exploratory, observational and inconclusive.
- Aardvark appointed David Zhang, Ph.D., MBA, as an independent director in October 2026.
$AARD Insider Trading Activity
$AARD insiders have traded $AARD stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $AARD stock by insiders over the last 6 months:
- NELSON SUN (See Remarks) has made 0 purchases and 2 sales selling 76,754 shares for an estimated $394,957.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AARD Hedge Fund Activity
We have seen 22 institutional investors add shares of $AARD stock to their portfolio, and 56 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 605,526 shares (-76.4%) from their portfolio in Q2 2026, for an estimated $3,487,829
- ECOR1 CAPITAL, LLC added 396,194 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,282,077
- AQR CAPITAL MANAGEMENT LLC added 345,754 shares (+257.1%) to their portfolio in Q2 2026, for an estimated $1,991,543
- TETRAGON PARTNERS GP LTD removed 316,621 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,823,736
- RENAISSANCE TECHNOLOGIES LLC removed 70,792 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $407,761
- NORTHERN TRUST CORP removed 60,519 shares (-68.3%) from their portfolio in Q2 2026, for an estimated $348,589
- TWO SIGMA INVESTMENTS, LP removed 54,978 shares (-33.7%) from their portfolio in Q2 2026, for an estimated $316,673
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.